OTCMKTS:PPTDF PeptiDream (PPTDF) Stock Price, News & Analysis $17.00 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest Get PeptiDream alerts: Email Address About PeptiDream Stock (OTCMKTS:PPTDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PeptiDream alerts:Sign Up Key Stats Today's Range$17.00▼$17.0050-Day Range$14.30▼$18.0052-Week Range$7.40▼$18.00Volume1 shsAverage Volume581 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.Read More… WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Receive PPTDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PeptiDream and its competitors with MarketBeat's FREE daily newsletter. Email Address PPTDF Stock News HeadlinesPeptiDream Inc. (OTCMKTS:PPTDF) Short Interest Down 23.6% in SeptemberSeptember 29 at 12:15 AM | americanbankingnews.comSee More Headlines PPTDF Stock Analysis - Frequently Asked Questions How have PPTDF shares performed this year? PeptiDream's stock was trading at $8.56 at the beginning of the year. Since then, PPTDF shares have increased by 98.6% and is now trading at $17.00. View the best growth stocks for 2024 here. How do I buy shares of PeptiDream? Shares of PPTDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:PPTDF CUSIPN/A CIKN/A Webwww.peptidream.com Phone81-4-4270-1300FaxN/AEmployees603Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (OTCMKTS:PPTDF) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PeptiDream Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PeptiDream With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.